{
    "hands_on_practices": [
        {
            "introduction": "The principle of stoichiometric neutralization is fundamental to many antidotes that work by direct binding. This practice explores the dosing of Digoxin Immune Fab, an antibody fragment that binds digoxin. It provides a crucial opportunity to apply core pharmacokinetic principles, such as calculating the total body burden of a toxin from either serum concentration and volume of distribution ($M_{\\text{body}} = C_s \\times V_d$) or from ingestion history and bioavailability ($M_{\\text{absorbed}} = \\text{Dose} \\times F$). By working through these parallel approaches , you will develop a robust understanding of how to quantify the amount of antidote needed to completely neutralize a toxin distributed throughout the body.",
            "id": "4522768",
            "problem": "A patient with severe digoxin toxicity requires urgent neutralization with Digoxin Immune Fragment antigen-binding (Fab). In clinical pharmacology, the initial dose of Fab can be derived from first principles using two independent approaches: a concentration-based mass-balance and an ingestion-based binding requirement. Use the following scenario and assumptions, and show all derivations from core definitions.\n\nScenario and assumptions:\n- The patient’s serum digoxin concentration, measured at distribution equilibrium (drawn at least $12$ hours after the last dose), is $C_{\\text{s}} = \\frac{16}{3}$ ng/mL.\n- The patient’s body weight is $W = 75$ kg.\n- Assume the typical apparent volume of distribution of digoxin is $V_{\\text{d}} = 5$ L/kg.\n- Each vial of Digoxin Immune Fab binds exactly $0.5$ mg of digoxin.\n- The patient ingested $N = 10$ oral tablets, each containing $0.25$ mg of digoxin, in a single episode.\n- The oral bioavailability of digoxin is $F = 0.8$.\n- No interventions that materially alter absorption or distribution have occurred (for example, no activated charcoal within $2$ hours, and no lipid emulsion), and renal dysfunction does not change the initial neutralization requirement.\n\nTasks:\n1. Starting from the definition of mass in the body as the product of concentration and volume, derive the concentration-based expression for the number of vials required in terms of $C_{\\text{s}}$, $W$, $V_{\\text{d}}$, the unit conversions from ng/mL to mg/L, and the per-vial binding capacity of Digoxin Immune Fab. Then, compute the numerical value for this patient.\n2. Starting from the definition of absorbed dose as the product of the ingested dose and oral bioavailability, derive the ingestion-based expression for the number of vials required in terms of $N$, tablet strength, $F$, and the per-vial binding capacity. Then, compute the numerical value for this patient.\n3. Provide the clinically appropriate initial vial count as the minimum whole number of vials that will bind the computed digoxin burden. If the two derivations differ, justify using the larger value as the initial dose to ensure complete neutralization of the circulating and tissue compartments. If they agree, report that number.\n\nReport your final answer as an exact integer number of vials. Do not round by significant figures; instead, provide the exact integer implied by your derivations.",
            "solution": "The problem requires the calculation of the initial dose of Digoxin Immune Fab in vials using two different methods: a concentration-based method and an ingestion-based method. Finally, a single clinically appropriate dose must be determined.\n\n1.  **Concentration-Based Derivation**\n    The fundamental principle is that the total mass of a drug in the body, which we will denote as $M_{\\text{body}}$, can be estimated from its serum concentration, $C_{\\text{s}}$, and its apparent volume of distribution, $V_{\\text{d}}$. The total apparent volume of distribution for the patient, $V_{\\text{total}}$, is the product of the specific volume of distribution (per unit weight), $V_{\\text{d}}$, and the patient's body weight, $W$.\n    $$V_{\\text{total}} = V_{\\text{d}} \\times W$$\n    The total body burden of the drug is then the product of the serum concentration and the total volume of distribution.\n    $$M_{\\text{body}} = C_{\\text{s}} \\times V_{\\text{total}} = C_{\\text{s}} \\times V_{\\text{d}} \\times W$$\n    A critical step is ensuring unit consistency. The given concentration $C_{\\text{s}}$ is in units of $\\text{ng/mL}$, $V_{\\text{d}}$ is in $\\text{L/kg}$, and $W$ is in $\\text{kg}$. The binding capacity of the antidote is given in $\\text{mg}$. We must convert these units to a consistent system. A convenient choice is to calculate the mass in $\\text{mg}$ and volume in $\\text{L}$. The conversion from $\\text{ng/mL}$ to $\\text{mg/L}$ is derived as follows:\n    $$1 \\frac{\\text{ng}}{\\text{mL}} = 1 \\frac{\\text{ng}}{\\text{mL}} \\times \\frac{1000 \\text{ mL}}{1 \\text{ L}} \\times \\frac{1 \\text{ mg}}{10^6 \\text{ ng}} = \\frac{10^3}{10^6} \\frac{\\text{mg}}{\\text{L}} = 10^{-3} \\frac{\\text{mg}}{\\text{L}}$$\n    Therefore, to express $C_{\\text{s}}$ in $\\text{mg/L}$, we multiply its value in $\\text{ng/mL}$ by $10^{-3}$. Let's denote the concentration in $\\text{mg/L}$ as $C'_{\\text{s}}$. The mass of digoxin in the body, in $\\text{mg}$, is:\n    $$M_{\\text{body}} \\text{ (in mg)} = C'_{\\text{s}} \\text{ (in mg/L)} \\times V_{\\text{total}} \\text{ (in L)}$$\n    $$M_{\\text{body}} = (C_{\\text{s}} \\times 10^{-3}) \\times (V_{\\text{d}} \\times W)$$\n    The number of vials required, $N_{\\text{vials, conc}}$, is this total mass divided by the binding capacity per vial, $B_{\\text{vial}}$, which is given as $0.5 \\text{ mg}$. The derived expression is:\n    $$N_{\\text{vials, conc}} = \\frac{C_{\\text{s}} \\times V_{\\text{d}} \\times W \\times 10^{-3}}{B_{\\text{vial}}}$$\n    We now substitute the provided values: $C_{\\text{s}} = \\frac{16}{3} \\text{ ng/mL}$, $W = 75 \\text{ kg}$, $V_{\\text{d}} = 5 \\text{ L/kg}$, and $B_{\\text{vial}} = 0.5 \\text{ mg}$.\n    First, we calculate the total body burden, $M_{\\text{body}}$:\n    $$M_{\\text{body}} = \\left(\\frac{16}{3}\\right) \\times 5 \\times 75 \\times 10^{-3} \\text{ mg}$$\n    $$M_{\\text{body}} = \\frac{16 \\times 5 \\times 75}{3} \\times 10^{-3} \\text{ mg} = (16 \\times 5 \\times 25) \\times 10^{-3} \\text{ mg}$$\n    $$M_{\\text{body}} = (16 \\times 125) \\times 10^{-3} \\text{ mg} = 2000 \\times 10^{-3} \\text{ mg} = 2 \\text{ mg}$$\n    Next, we compute the number of vials based on this mass:\n    $$N_{\\text{vials, conc}} = \\frac{2 \\text{ mg}}{0.5 \\text{ mg/vial}} = 4 \\text{ vials}$$\n\n2.  **Ingestion-Based Derivation**\n    The second method calculates the required dose based on the amount of drug absorbed following ingestion. The total mass of drug ingested, $D_{\\text{ingested}}$, is the product of the number of tablets taken, $N$, and the strength (mass of drug) per tablet, $S_{\\text{tablet}}$.\n    $$D_{\\text{ingested}} = N \\times S_{\\text{tablet}}$$\n    The mass of drug that enters the systemic circulation, $M_{\\text{absorbed}}$, is the ingested dose multiplied by the oral bioavailability fraction, $F$.\n    $$M_{\\text{absorbed}} = D_{\\text{ingested}} \\times F = N \\times S_{\\text{tablet}} \\times F$$\n    The number of vials required, $N_{\\text{vials, ing}}$, is this absorbed mass divided by the binding capacity per vial, $B_{\\text{vial}}$. The derived expression is:\n    $$N_{\\text{vials, ing}} = \\frac{N \\times S_{\\text{tablet}} \\times F}{B_{\\text{vial}}}$$\n    We now substitute the provided values: $N = 10$, $S_{\\text{tablet}} = 0.25 \\text{ mg}$, $F = 0.8$, and $B_{\\text{vial}} = 0.5 \\text{ mg}$.\n    First, we calculate the total absorbed mass, $M_{\\text{absorbed}}$:\n    $$M_{\\text{absorbed}} = 10 \\times 0.25 \\text{ mg} \\times 0.8 = 2.5 \\text{ mg} \\times 0.8 = 2 \\text{ mg}$$\n    Next, we compute the number of vials based on this mass:\n    $$N_{\\text{vials, ing}} = \\frac{2 \\text{ mg}}{0.5 \\text{ mg/vial}} = 4 \\text{ vials}$$\n\n3.  **Clinically Appropriate Initial Vial Count**\n    The concentration-based method yields a requirement of $4$ vials. The ingestion-based method also yields a requirement of $4$ vials. According to the problem instructions, if the two derivations agree, that number should be reported. The problem asks for the minimum whole number of vials required. Since the calculated digoxin burden of $2 \\text{ mg}$ is precisely neutralized by $4$ vials, no rounding is necessary. The clinically appropriate initial dose is $4$ vials.",
            "answer": "$$\n\\boxed{4}\n$$"
        },
        {
            "introduction": "Building on the concept of stoichiometric neutralization, this exercise introduces the critical dimension of time. Antidote dosing must often account for the drug's own elimination, as the amount of substance to be neutralized decreases over time. This problem focuses on reversing the anticoagulant heparin with its direct antagonist, protamine sulfate. You will apply first-order elimination kinetics and the principle of superposition to calculate the total amount of heparin currently active in the body from a series of previous bolus doses . This skill is essential for precise antidote administration in dynamic clinical settings.",
            "id": "4522780",
            "problem": "A patient undergoing an urgent vascular procedure has received multiple intravenous boluses of unfractionated heparin over the past two hours. The clinical goal is to compute the neutralizing dose of protamine sulfate to be administered now, using the mechanistic relationships between heparin pharmacokinetics and protamine–heparin stoichiometry.\n\nAssume the following foundational facts:\n- Intravenous unfractionated heparin exhibits first-order elimination with elimination half-life $t_{1/2} = 60$ minutes at therapeutic concentrations, and its anticoagulant activity at time $t$ is directly proportional to the amount of heparin remaining in the body.\n- For an instantaneous intravenous bolus heparin dose, superposition applies for first-order elimination so that contributions from separate boluses add linearly.\n- Protamine sulfate neutralizes unfractionated heparin by direct binding in an approximately fixed stoichiometric ratio of $1$ mg protamine per $100$ international units of active heparin.\n\nThere is no ongoing infusion. The recorded heparin bolus history relative to the current time (defined as $t=0$) is:\n- $5{,}000$ units at $t=-10$ minutes,\n- $8{,}000$ units at $t=-35$ minutes,\n- $4{,}000$ units at $t=-70$ minutes,\n- $6{,}000$ units at $t=-120$ minutes.\n\nUsing only the assumptions above and first principles of first-order elimination kinetics, determine the single protamine dose to fully neutralize the currently active heparin, expressed in milligrams. Round your final answer to three significant figures and express the final dose in mg.",
            "solution": "The amount of a drug, $A(t)$, remaining in the body at a time $t$ after a single intravenous bolus dose $A_0$, assuming first-order elimination, is described by the equation:\n$$A(t) = A_0 \\exp(-kt)$$\nwhere $k$ is the first-order elimination rate constant.\n\nThe rate constant $k$ is related to the elimination half-life, $t_{1/2}$, by the formula:\n$$k = \\frac{\\ln(2)}{t_{1/2}}$$\nGiven $t_{1/2} = 60$ minutes, the elimination rate constant for heparin is:\n$$k = \\frac{\\ln(2)}{60} \\text{ min}^{-1}$$\nThe problem states that the principle of superposition applies. Therefore, the total amount of heparin remaining in the body at the current time ($t=0$), denoted as $A_{total}$, is the sum of the amounts remaining from each individual bolus dose.\n\nFor a dose $D_i$ administered at time $t_i$ (where $t_i < 0$), the time elapsed until the current time $t=0$ is $\\Delta t_i = 0 - t_i = -t_i$. The amount of heparin remaining from this single dose at $t=0$ is $A_i(0) = D_i \\exp(-k \\Delta t_i)$.\n\nWe calculate the amount remaining from each of the four boluses:\n\n1.  Dose $D_1 = 5{,}000$ units at $t_1 = -10$ min. The time elapsed is $\\Delta t_1 = 10$ min.\n    The remaining amount is $A_1 = 5000 \\exp(-k \\cdot 10)$.\n\n2.  Dose $D_2 = 8{,}000$ units at $t_2 = -35$ min. The time elapsed is $\\Delta t_2 = 35$ min.\n    The remaining amount is $A_2 = 8000 \\exp(-k \\cdot 35)$.\n\n3.  Dose $D_3 = 4{,}000$ units at $t_3 = -70$ min. The time elapsed is $\\Delta t_3 = 70$ min.\n    The remaining amount is $A_3 = 4000 \\exp(-k \\cdot 70)$.\n\n4.  Dose $D_4 = 6{,}000$ units at $t_4 = -120$ min. The time elapsed is $\\Delta t_4 = 120$ min.\n    The remaining amount is $A_4 = 6000 \\exp(-k \\cdot 120)$.\n\nThe total active heparin at $t=0$ is the sum $A_{total} = A_1 + A_2 + A_3 + A_4$:\n$$A_{total} = 5000 \\exp(-10k) + 8000 \\exp(-35k) + 4000 \\exp(-70k) + 6000 \\exp(-120k)$$\nSubstituting $k = \\frac{\\ln(2)}{60}$:\n$$A_{total} = 5000 \\exp\\left(-\\frac{10}{60}\\ln(2)\\right) + 8000 \\exp\\left(-\\frac{35}{60}\\ln(2)\\right) + 4000 \\exp\\left(-\\frac{70}{60}\\ln(2)\\right) + 6000 \\exp\\left(-\\frac{120}{60}\\ln(2)\\right)$$\nUsing the identity $\\exp(a \\ln(b)) = b^a$, this can be rewritten as:\n$$A_{total} = 5000 \\cdot 2^{-10/60} + 8000 \\cdot 2^{-35/60} + 4000 \\cdot 2^{-70/60} + 6000 \\cdot 2^{-120/60}$$\n$$A_{total} = 5000 \\cdot 2^{-1/6} + 8000 \\cdot 2^{-7/12} + 4000 \\cdot 2^{-7/6} + 6000 \\cdot 2^{-2}$$\nNow, we compute the numerical values for each term:\n-   $A_1 = 5000 \\cdot 2^{-1/6} \\approx 5000 \\cdot 0.8908987 \\approx 4454.49$ units\n-   $A_2 = 8000 \\cdot 2^{-7/12} \\approx 8000 \\cdot 0.6674199 \\approx 5339.36$ units\n-   $A_3 = 4000 \\cdot 2^{-7/6} \\approx 4000 \\cdot 0.4454494 \\approx 1781.80$ units\n-   $A_4 = 6000 \\cdot 2^{-2} = 6000 \\cdot 0.25 = 1500.00$ units\n\nSumming these amounts gives the total active heparin:\n$$A_{total} \\approx 4454.49 + 5339.36 + 1781.80 + 1500.00 = 13075.65 \\text{ units}$$\nThe problem states that protamine sulfate neutralizes heparin in a stoichiometric ratio of $1$ mg of protamine for every $100$ units of heparin. Let $S_R$ be this ratio:\n$$S_R = \\frac{1 \\text{ mg protamine}}{100 \\text{ units heparin}}$$\nThe required dose of protamine, $D_{protamine}$, is therefore:\n$$D_{protamine} = A_{total} \\cdot S_R = 13075.65 \\text{ units} \\times \\frac{1 \\text{ mg}}{100 \\text{ units}}$$\n$$D_{protamine} \\approx 130.7565 \\text{ mg}$$\nThe problem requires the final answer to be rounded to three significant figures. The number $130.7565$ is rounded to $131$.\n\nTherefore, the calculated dose of protamine sulfate to be administered is $131$ mg.",
            "answer": "$$\n\\boxed{131}\n$$"
        },
        {
            "introduction": "Effective antidote therapy often requires moving beyond single-dose reversal to designing a continuous regimen, especially when a short-acting antagonist is used against a long-acting toxin. This practice tackles the classic clinical challenge of preventing renarcotization after an opioid overdose by designing a continuous naloxone infusion. This advanced problem requires you to integrate receptor theory—calculating the antagonist concentration needed to maintain agonist occupancy below a safety threshold—with steady-state pharmacokinetics to determine the necessary infusion rate ($R = \\mathrm{CL} \\times C_{ss}$) . Mastering this synthesis of pharmacodynamics and pharmacokinetics is key to designing rational, mechanism-based therapeutic strategies.",
            "id": "4522707",
            "problem": "An adult patient experiencing respiratory depression from a long-acting opioid is reversed with a single intravenous bolus of naloxone. To minimize the risk of renarcotization due to the mismatch between opioid and naloxone elimination, design a continuous naloxone infusion that maintains methadone (the opioid) receptor occupancy at the mu-opioid receptor (MOR) below a chosen safety threshold of $f_{\\ast} = 0.2$ for $6$ hours. Assume competitive binding at the MOR between methadone (agonist) and naloxone (antagonist) governed by the law of mass action at equilibrium, and a one-compartment pharmacokinetic model for naloxone with constant clearance.\n\nUse the following scientifically plausible parameters:\n- Methadone effect-site (free) concentration $[O] = 50\\,\\mathrm{nM}$ over the $6$-hour period (reflecting its long half-life).\n- Methadone dissociation constant for MOR $K_{d,O} = 10\\,\\mathrm{nM}$.\n- Naloxone dissociation constant for MOR $K_{d,N} = 1\\,\\mathrm{nM}$.\n- Naloxone half-life $t_{1/2,N} = 1\\,\\mathrm{h}$.\n- Naloxone clearance $\\mathrm{CL}_{N} = 30\\,\\mathrm{L\\,h^{-1}}$ (consistent with $t_{1/2,N}$ via an appropriate distribution volume in this patient).\n- Naloxone molar mass $M_{N} = 327\\,\\mathrm{g\\,mol^{-1}}$.\n\nAssume the effect-site concentration of naloxone equals its plasma concentration under steady-state infusion, and ignore distributional delays. Derive from first principles the minimum naloxone steady-state concentration $[N]$ that ensures the methadone occupancy $f_{O}$ at MOR satisfies $f_{O} \\le f_{\\ast}$ under competitive binding. Then, using mass balance at steady state, determine the naloxone infusion rate $R$ that maintains this $[N]$.\n\nExpress your final answer as the infusion rate in $\\mathrm{mg\\,h^{-1}}$ and round your answer to three significant figures.",
            "solution": "The solution is developed in two main parts: first, determining the required steady-state concentration of naloxone based on receptor binding theory, and second, calculating the infusion rate needed to achieve this concentration based on pharmacokinetic principles.\n\n**Part 1: Determination of Required Naloxone Concentration**\n\nThe interaction between the opioid agonist (methadone, $O$) and the competitive antagonist (naloxone, $N$) at the mu-opioid receptor ($R$) is described by the law of mass action at equilibrium. The relevant reactions are:\n$$\nO + R \\rightleftharpoons OR \\quad \\text{with dissociation constant } K_{d,O} = \\frac{[O][R]}{[OR]}\n$$\n$$\nN + R \\rightleftharpoons NR \\quad \\text{with dissociation constant } K_{d,N} = \\frac{[N][R]}{[NR]}\n$$\nHere, $[O]$, $[N]$, and $[R]$ are the concentrations of free opioid, free naloxone, and free receptors, respectively. $[OR]$ and $[NR]$ are the concentrations of opioid-bound and naloxone-bound receptors.\n\nThe total concentration of receptors, $[R_T]$, is the sum of free and bound receptors:\n$$\n[R_T] = [R] + [OR] + [NR]\n$$\nThe fractional occupancy of the receptors by the opioid, $f_O$, is defined as the ratio of opioid-bound receptors to the total number of receptors:\n$$\nf_O = \\frac{[OR]}{[R_T]} = \\frac{[OR]}{[R] + [OR] + [NR]}\n$$\nTo express $f_O$ in terms of the drug concentrations and dissociation constants, we first rearrange the equilibrium equations to express $[OR]$ and $[NR]$ in terms of $[R]$:\n$$\n[OR] = \\frac{[O][R]}{K_{d,O}}\n$$\n$$\n[NR] = \\frac{[N][R]}{K_{d,N}}\n$$\nSubstituting these into the equation for $f_O$ and dividing the numerator and denominator by $[R]$ (which is non-zero) yields:\n$$\nf_O = \\frac{\\frac{[O][R]}{K_{d,O}}}{[R] + \\frac{[O][R]}{K_{d,O}} + \\frac{[N][R]}{K_{d,N}}} = \\frac{\\frac{[O]}{K_{d,O}}}{1 + \\frac{[O]}{K_{d,O}} + \\frac{[N]}{K_{d,N}}}\n$$\nThe problem requires that the opioid occupancy be maintained at or below a safety threshold, $f_O \\le f_{\\ast}$. To find the minimum required concentration of naloxone, $[N]$, that achieves this, we set the occupancy to its maximum allowable value, $f_O = f_{\\ast}$:\n$$\nf_{\\ast} = \\frac{\\frac{[O]}{K_{d,O}}}{1 + \\frac{[O]}{K_{d,O}} + \\frac{[N]_{ss}}{K_{d,N}}}\n$$\nWe now solve this equation for $[N]$. This concentration will be the target steady-state concentration, $[N]_{ss}$.\n$$\nf_{\\ast} \\left( 1 + \\frac{[O]}{K_{d,O}} + \\frac{[N]_{ss}}{K_{d,N}} \\right) = \\frac{[O]}{K_{d,O}}\n$$\n$$\n1 + \\frac{[O]}{K_{d,O}} + \\frac{[N]_{ss}}{K_{d,N}} = \\frac{1}{f_{\\ast}} \\frac{[O]}{K_{d,O}}\n$$\n$$\n\\frac{[N]_{ss}}{K_{d,N}} = \\frac{1}{f_{\\ast}} \\frac{[O]}{K_{d,O}} - \\frac{[O]}{K_{d,O}} - 1\n$$\n$$\n\\frac{[N]_{ss}}{K_{d,N}} = \\frac{[O]}{K_{d,O}} \\left( \\frac{1}{f_{\\ast}} - 1 \\right) - 1 = \\frac{[O]}{K_{d,O}} \\left( \\frac{1 - f_{\\ast}}{f_{\\ast}} \\right) - 1\n$$\n$$\n[N]_{ss} = K_{d,N} \\left[ \\frac{[O]}{K_{d,O}} \\left( \\frac{1 - f_{\\ast}}{f_{\\ast}} \\right) - 1 \\right]\n$$\nNow, we substitute the given values: $[O] = 50\\,\\mathrm{nM}$, $K_{d,O} = 10\\,\\mathrm{nM}$, $K_{d,N} = 1\\,\\mathrm{nM}$, and $f_{\\ast} = 0.2$.\n$$\n[N]_{ss} = (1\\,\\mathrm{nM}) \\left[ \\frac{50\\,\\mathrm{nM}}{10\\,\\mathrm{nM}} \\left( \\frac{1 - 0.2}{0.2} \\right) - 1 \\right]\n$$\n$$\n[N]_{ss} = (1\\,\\mathrm{nM}) \\left[ 5 \\left( \\frac{0.8}{0.2} \\right) - 1 \\right]\n$$\n$$\n[N]_{ss} = (1\\,\\mathrm{nM}) [ 5(4) - 1 ] = (1\\,\\mathrm{nM}) [ 20 - 1 ]\n$$\n$$\n[N]_{ss} = 19\\,\\mathrm{nM}\n$$\nThe minimum steady-state concentration of naloxone required is $19\\,\\mathrm{nM}$.\n\n**Part 2: Calculation of the Naloxone Infusion Rate**\n\nFor a drug administered via continuous intravenous infusion described by a one-compartment model, a steady state is reached when the rate of drug administration equals the rate of drug elimination. Let $R$ be the infusion rate.\n$$\n\\text{Rate of Administration} = \\text{Rate of Elimination}\n$$\nThe rate of elimination is the product of the drug's clearance ($\\mathrm{CL}$) and its steady-state plasma concentration ($C_{ss}$). The problem assumes the effect-site concentration equals the plasma concentration, so $[N]_{ss}$ can be used for $C_{ss}$.\n$$\nR = \\mathrm{CL}_{N} \\times [N]_{ss}\n$$\nThis equation gives the infusion rate in moles per unit time, as $[N]_{ss}$ is a molar concentration. To find the infusion rate in mass per unit time (as required), we must multiply by the molar mass of naloxone, $M_N$.\n$$\nR_{\\text{mass}} = R_{\\text{molar}} \\times M_N = \\mathrm{CL}_{N} \\times [N]_{ss} \\times M_N\n$$\nWe must be careful with units. We are given:\n- $\\mathrm{CL}_{N} = 30\\,\\mathrm{L\\,h^{-1}}$\n- $[N]_{ss} = 19\\,\\mathrm{nM} = 19 \\times 10^{-9}\\,\\mathrm{mol\\,L^{-1}}$\n- $M_{N} = 327\\,\\mathrm{g\\,mol^{-1}}$\n\nThe problem asks for the rate in $\\mathrm{mg\\,h^{-1}}$.\n$$\nR = (30\\,\\mathrm{L\\,h^{-1}}) \\times (19 \\times 10^{-9}\\,\\mathrm{mol\\,L^{-1}}) \\times (327\\,\\mathrm{g\\,mol^{-1}})\n$$\nThe units $(\\mathrm{L})$ and $(\\mathrm{mol})$ cancel, leaving $\\mathrm{g\\,h^{-1}}$.\n$$\nR = (30 \\times 19 \\times 327) \\times 10^{-9}\\,\\mathrm{g\\,h^{-1}}\n$$\n$$\nR = 186390 \\times 10^{-9}\\,\\mathrm{g\\,h^{-1}} = 0.00018639\\,\\mathrm{g\\,h^{-1}}\n$$\nTo convert from grams to milligrams, we multiply by $1000\\,\\mathrm{mg\\,g^{-1}}$.\n$$\nR = 0.00018639\\,\\mathrm{g\\,h^{-1}} \\times 1000\\,\\mathrm{mg\\,g^{-1}} = 0.18639\\,\\mathrm{mg\\,h^{-1}}\n$$\nThe problem requires the answer to be rounded to three significant figures.\n$$\nR \\approx 0.186\\,\\mathrm{mg\\,h^{-1}}\n$$\nThus, a continuous infusion rate of $0.186\\,\\mathrm{mg\\,h^{-1}}$ is required to maintain the methadone receptor occupancy below the safety threshold of $20\\%$.",
            "answer": "$$\n\\boxed{0.186}\n$$"
        }
    ]
}